Publicacións en colaboración con investigadores/as de Universidade de Santiago de Compostela (17)

2023

  1. Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies’ Determination against ELISA

    Pharmaceutics, Vol. 15, Núm. 11

  2. Ileal reservoir-associated complications in ulcerative colitis versus familial adenomatous polyposis: Impact on patient quality of life

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 1, pp. 39-47

  3. Is Occupation a Risk Factor for Developing Inflammatory Bowel Disease? A Case–Control Study

    Crohn's and Colitis 360, Vol. 5, Núm. 4

  4. Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated with Internal Fistulizing Disease: BIOSCOPE Study from GETECCU

    American Journal of Gastroenterology, Vol. 118, Núm. 6, pp. 1036-1046

2022

  1. Characterisation of the blood RNA host response underpinning severity in COVID-19 patients

    Scientific Reports, Vol. 12, Núm. 1

  2. Radon exposure and inflammatory bowel disease in a radon prone area

    Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, Vol. 114, Núm. 7, pp. 405-409

2021

  1. Targeted 1H NMR metabolomics and immunological phenotyping of human fresh blood and serum samples discriminate between healthy individuals and inflammatory bowel disease patients treated with anti-TNF

    Journal of Molecular Medicine, Vol. 99, Núm. 9, pp. 1251-1264

2020

  1. A Qualitative Research for Defining Meaningful Attributes for the Treatment of Inflammatory Bowel Disease from the Patient Perspective

    Patient, Vol. 13, Núm. 3, pp. 317-325

2018

  1. Longitudinal PET/CT evaluation of TNBS-induced inflammatory bowel disease rat model

    International Journal of Pharmaceutics, Vol. 549, Núm. 1-2, pp. 335-342

  2. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) and the Association of Crohn's Disease and Ulcerative Colitis Patients (ACCU) in the management of psychological problems in Inflammatory Bowel Disease patients

    Gastroenterologia y Hepatologia

  3. The psychosocial impact of inflammatory bowel disease and its management. From the patients’ perspective

    Gastroenterologia y Hepatologia, Vol. 41, Núm. 10, pp. 640-642

2014

  1. Letter: Psychological remission - A future endpoint in inflammatory bowel disease?

    Alimentary Pharmacology and Therapeutics

  2. Psychological factors are associated with changes in the health-related quality of life in inflammatory bowel disease

    Inflammatory Bowel Diseases, Vol. 20, Núm. 1, pp. 92-102

2013

  1. How do psychological variables influence coping strategies in inflammatory bowel disease?

    Journal of Crohn's and Colitis, Vol. 7, Núm. 6

2012

  1. Influence of alexithymia on health-related quality of life in inflammatory bowel disease: Are there any related factors?

    Scandinavian Journal of Gastroenterology, Vol. 47, Núm. 4, pp. 445-453

  2. Letter: Surgery for ulcerative colitis mostly follows anti-TNF drugs - A new 'therapeutic package'?

    Alimentary Pharmacology and Therapeutics

2011

  1. A pharmacogenetics study of TPMT and ITPA genes detects a relationship with side effects and clinical response in patients with inflammatory bowel disease receiving azathioprine

    Journal of Gastrointestinal and Liver Diseases, Vol. 20, Núm. 3, pp. 247-253